Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.
Fiche publication
Date publication
février 2022
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Dr FOUCHER Pascal, Dr MENNECIER Bertrand, Dr DORY Anne
Tous les auteurs :
Slimano F, Le Bozec A, Cransac A, Foucher P, Lesauvage F, Delclaux B, Dory A, Mennecier B, Bertrand B, Gubeno-Dumon MC, Dukic S, Mongaret C, Bouché O, Hettler D, Boulin M, Dewolf M, Kanagaratnam L
Lien Pubmed
Résumé
Pemetrexed is associated with hematological toxicity. Drug-drug interactions (DDIs) between methotrexate and proton pump inhibitors (PPIs) induce a higher risk of hematological toxicity due to the inhibition of methotrexate excretion by PPIs. As pemetrexed and methotrexate are both excreted by human organic anion transporter 3 (hOAT3), this study investigates the hypothetical DDI between pemetrexed and PPIs in lung cancer patients. The primary objective was the occurrence of severe (grade ≥ 3) hematological toxicity. The secondary objectives were to describe the type of hematological toxicity and associated clinical consequences (NCT03537833).
Mots clés
Drug interactions, Hematological toxicity, Organic anion Transporters-3, Pemetrexed, Proton pump inhibitors
Référence
Lung Cancer. 2022 Feb 24;166:114-121